91345-62-9

Basic information

• Product Name: 1-(4-BROMOBENZYL)PIPERAZINE
• Synonyms: Albb-000378;1-(4-bromobenzyl)piperazine(SALTDATA: HCl);1-(4-BroMobenzyl)piperazine 2HCl;1- (4- bromine phenyl) piperazine hydrochloride
• CAS NO: 91345-62-9
• Molecular Formula: C₁₁H₁₅BrN₂
• Molecular Weight: 255.16
• Product Categories: Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Piperazines;PiperazinesHeterocyclic Building Blocks;Building Blocks;C11;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 91345-62-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 56-62 °C(lit.)
• Boiling Point: 112-116 °C0.3 mm Hg(lit.)
• Flash Point: 153 °C
• Appearance: White to pale brown/Solid
• Density: 1.356
• Vapor Pressure: 0.000178mmHg at 25°C
• Refractive Index: 1.575
• CAS DataBase Reference: 1-(4-BROMOBENZYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BROMOBENZYL)PIPERAZINE(91345-62-9)
• EPA Substance Registry System: 1-(4-BROMOBENZYL)PIPERAZINE(91345-62-9)

Safety Data

• Hazard Codes: C,Xn
• Statements: 22-34-36/37/38
• Safety Statements: 26-36/37/39-45-36
• RIDADR: UN 3259 8/PG 3
• WGK Germany: 2
• F: 10-34
• HazardClass: IRRITANT
• Hazardous Substances Data: 91345-62-9(Hazardous Substances Data)

Usage

General Description

1-(4-Bromobenzyl)piperazine is a chemical compound with the molecular formula C11H14BrN. It is a piperazine derivative that contains a benzyl group substituted with a bromine atom. 1-(4-Bromobenzyl)piperazine is commonly used in the field of medicinal chemistry for the development of drugs targeting various receptors, such as dopamine and serotonin receptors. The presence of the piperazine moiety in the molecule makes it a potential candidate for the development of pharmaceuticals targeting the central nervous system. Additionally, the bromine atom in the benzyl group can impart specific chemical and biological properties to the compound, making it useful for further research and drug development.

InChI:InChI=1/C11H15BrN2/c12-11-3-1-10(2-4-11)9-14-7-5-13-6-8-14/h1-4,13H,5-9H2

Upstream product

• 844891-10-7 tert-butyl 4-[(4-bromophenyl)methyl]piperazine-1-carboxylate 
• 110-85-0 piperazine 
• 589-17-3 p-bromobenzyl chloride 
• 106-38-7 para-bromotoluene 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 1218949-50-8 2-[(4-bromobenzyl)piperazin-1-yl]-1-[3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl]ethanone 
• 1296135-55-1 N-benzyl-2-[4-(4-bromobenzyl)piperazin-1-yl]pyrimidin-4-amine 
• 1384110-82-0 C₂₃H₂₅BrN₆O₂ 
• 1383276-04-7 C₂₀H₂₃BrN₂O 
• 1393107-99-7 (S)-2-amino-3-(4-(4-bromobenzyl)piperazin-1-yl)propionic acid 
• 96293-17-3 (S)-N-(2-benzoylphenyl)-1-benzylpyrrolidine-2-carboxamide 
• 1398718-03-0 (S)-1-amino-N-(1-cyano-2-(4'-((4-(oxazol-2-ylmethyl)piperazin-1-yl)methyl)biphenyl-4-yl)ethyl)cyclohexanecarboxamide 
• 1398718-72-3 PZ₁₀₅₇-2 
• 1398718-70-1 C₁₅H₁₈BrN₃O 
• 1403353-37-6 C₁₈H₁₈BrN₅O 

Relevant articles and documents

SYNTHESIS, CRYSTAL STRUCTURE, AND BIOLOGICAL EVALUATION OF (E)-1-(4-(4-BROMOBENZYL)PIPERAZIN-1-YL)- 3-(4-CHLOROPHENYL)PROP-2-EN-1-ONE

Abstract: Title compound (E)-1-(4-(4-bromobenzyl)piperazin-1-yl)-3-(4-chlorophenyl)prop-2-en-1-one (5) (C20H20BrClN2O, Mr?=?419.74) is designed, synthesized, and evaluated for its biological activity. Its structure is confirmed by FTIR, 1H and 13C NMR, HRMS, and X-ray single crystal diffraction. The structure is stabilized via inter- as well as intra- C–H…O interactions and intra hydrogen bonding C–H…N interactions. The Hirshfeld surface intermolecular interactions are studied using the crystal structure. The maximum surface area of the molecule is occupied by C–H…O interactions. In addition, the biological activity in vitro and in vivo of title compound 5 is also evaluated.

Design, synthesis and neuroprotective activities of novel cinnamide derivatives containing benzylpiperazine moiety

A new series of cinnamide derivatives 6a–l were synthesized by the reaction of acyl chlorides with various substituted benzylpiperazines. The structures were characterized by 1H NMR, 13C NMR, and HRMS. The potential neuroprotective activities of cinnamide analogs were evaluated in differentiated rat pheochromocytoma cells (PC12 cells) and in mice subjected to acute cerebral ischemia. Among the series, 6a, 6b, and 6c, featuring a 1,3-benzodioxole moiety, showed potent neuroprotection both in vivo and in vitro. The three compounds were selected and further studied to determine their mechanism of action. MTT assay, Hoechst 33342/PI double staining, and high content screening (HCS) revealed that pretreatment of the cells with 6a, 6b, and 6c has significantly decreased the extent of cell apoptosis in a dose-dependent manner. The results of western blot analysis demonstrated these compounds suppressed apoptosis of glutamate-induced PC12 cells via caspase-3 pathway. These compounds can be lead compounds for further discovery of neuroprotective agents for treating cerebral ischemic stroke.

Synthesis and receptor binding studies of novel 4,4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of σ1 ligands

This study presents the synthesis and biological evaluation of a new series of arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as sigma receptor ligands. It was found that a number of halogen substituted sulfonamides display relatively high and low affinities to σ1 and σ2 receptors, respectively. The σ1 affinities and subtype selectivities of four piperidine derivatives were also found to be generally comparable to those of piperazine analogues. Compared to σ1-Rs compounds with n = 0 and 2, those with n = 1 proved to have optimal length of carbon chain by exhibiting higher affinities. Within this series, the 4-benzyl-1-(3-iodobenzylsulfonyl)piperidine sigma ligand was identified with 96-fold σ1/σ2 selectivity ratio (Kiσ1 = 0.96 ± 0.05 nM and K iσ2 = 91.8 ± 8.1 nM).